The tweet was deleted by the author.
But we saved everything 🙂.
Karyopharm Therapeutics' new Phase 3 results from its SENTRY trial in myelofibrosis were featured in a late-breaking oral presentation at the EHA Annual Congress on June 14.
The EHA Scientific Program Committee selected these findings as one of the top presentations at the event, drawing significant attention from the hematology community. The recognition signals growing interest in Karyopharm Therapeutics' research in the field. Further details on the study and potential implications for treatment are expected from the conference proceedings.
Karyopharm Therapeutics previously presented Phase 3 SENTRY trial results in myelofibrosis at ASCO26. Those findings were also published in the Journal of Clinical Oncology. The company's ongoing data releases continue to draw attention from major medical conferences.